8.60
0.69%
-0.06
After Hours:
8.60
Overview
News
Price History
Option Chain
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is currently priced at $8.60, with a 24-hour trading volume of 2.15M.
It has seen a -0.69% decreased in the last 24 hours and a -8.32% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $8.75 pivot point. If it approaches the $8.57 support level, significant changes may occur.
Bausch Health Companies Inc Stock (BHC) Financials Data
Bausch Health Companies Inc (BHC) Revenue 2024
BHC reported a revenue (TTM) of $8.76 billion for the quarter ending December 31, 2023, a +7.79% rise year-over-year.
Bausch Health Companies Inc (BHC) Net Income 2024
BHC net income (TTM) was -$592.00 million for the quarter ending December 31, 2023, a -163.11% decrease year-over-year.
Bausch Health Companies Inc (BHC) Cash Flow 2024
BHC recorded a free cash flow (TTM) of $760.00 million for the quarter ending December 31, 2023, a +176.31% increase year-over-year.
Bausch Health Companies Inc (BHC) Earnings per Share 2024
BHC earnings per share (TTM) was -$1.62 for the quarter ending December 31, 2023, a -161.29% decline year-over-year.
Bausch Health Companies Inc Stock (BHC) Latest News
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Zacks Investment Research
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Zacks Investment Research
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Zacks Investment Research
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term
Zacks Investment Research
Tracking Carl Icahn's 13F Report - Q4 2023 Update
Seeking Alpha
About Bausch Health Companies Inc
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. The company also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others. In addition, it offers eye health products, such as contact lens; products that treat various eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for the treatment of cataracts, and vitreous and retinal eye conditions. Further, the company provides products in the therapeutic areas of epilepsy, migraines, depression, chronic pain, and rare diseases such, as huntington's disease; and oral health products for adult periodontitis and mouth dryness, as well as teeth-whitening. Additionally, it offers eye drops; skin care products, including moisturizers; and eye vitamins and mineral supplements, as well as neurology products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
Cap:
|
Volume (24h):